Dympna Waldron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dympna Waldron has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Eileen Mannion
School of Medicine, National University of Galway, Galway, Ireland
4 shared publicationsDavid Murphy
General Practitioner, Aran Islands, Galway, Ireland
3 shared publicationsJack Molony
Dublin North General Practitioner Scheme, Ireland
3 shared publicationsLaura Gaffney
School of Medicine, University of Galway, Ireland
3 shared publicationsBeth Molony
Department of Post Graduate Medicine, University of Limerick, Ireland
2 shared publications- David Murphy
St. Vincent's University Hospital , Dublin, Ireland
2 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by Elsevier in SSRN Electronic Journal
Positive versus Negative Language at End of Life: How we Speak Matters
Background: How clinicians speak to patients and families at end-of-life has profound implications for patient experience, family bereavement, and institutional care quality. Despite this, no widely adopted framework distinguishes positive from negative communicative framing in end-of-life practice. Objectives: Aim to synthesize evidence on language use in end-of-life communication; to present a clinically derived positive language framework; and to report audit data examining documentation of practice at a tertiary hospital. Methods: Narrative review of literature on end-of-life communication, empathy, quality of life, the patients’ voices, and resuscitation decision-making, supplemented by a retrospective audit of 51 patients who died at Galway University Hospital, Ireland, over a three-month period, examining documentation of the diagnosis of dying, resuscitation status, language, and family involvement. Results: 51 patients died during the audit period; 24 females, 27 males; mean age 64 years. Median time from admission to death was 15 days. 98% had resuscitation status documented, yet the diagnosis of ‘dying’ was clearly documented in only 50% of cases – predominantly by the palliative care team rather than the attending physician. Language used in documentation was more frequently negative than positive in framing. Significant ongoing interventions were recorded close to death including antibiotics (n=29), intravenous fluids (n=45), steroids (n=11) and chemotherapy (n=3). Conclusions :Consciously adopting positive language in end-of-life across verbal communications, documentation, resuscitation discussions, and family meetings, is a replicable clinical practice with the potential to reduce patient/family distress and improve care quality. A five-domain framework is presented. A prospective Vital Opioid Overdose Signs audit is underway to further validate outcomes of this approach. Protecting patients is an integral dimension of all healthcare, accompanied with honest discourse articulated through positive language at all times. How we speak matters just as much as speaking with honesty does. Understanding the patients’ views is paramount throughout the end-of-life journey.
- 20 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPositive versus Negative Language at End of Life: How we Speak Matters
Background: How clinicians speak to patients and families at end-of-life has profound implications for patient experience, family bereavement, and institutional care quality. Despite this, no widely adopted framework distinguishes positive from negative communicative framing in end-of-life practice. Objectives: Aim to synthesize evidence on language use in end-of-life communication; to present a clinically derived positive language framework; and to report audit data examining documentation of practice at a tertiary hospital. Methods: Narrative review of literature on end-of-life communication, empathy, quality of life, the patients’ voices, and resuscitation decision-making, supplemented by a retrospective audit of 51 patients who died at Galway University Hospital, Ireland, over a three-month period, examining documentation of the diagnosis of dying, resuscitation status, language, and family involvement. Results: 51 patients died during the audit period; 24 females, 27 males; mean age 64 years. Median time from admission to death was 15 days. 98% had resuscitation status documented, yet the diagnosis of ‘dying’ was clearly documented in only 50% of cases – predominantly by the palliative care team rather than the attending physician. Language used in documentation was more frequently negative than positive in framing. Significant ongoing interventions were recorded close to death including antibiotics (n=29), intravenous fluids (n=45), steroids (n=11) and chemotherapy (n=3). Conclusions :Consciously adopting positive language in end-of-life across verbal communications, documentation, resuscitation discussions, and family meetings, is a replicable clinical practice with the potential to reduce patient/family distress and improve care quality. A five-domain framework is presented. A prospective Vital Opioid Overdose Signs audit is underway to further validate outcomes of this approach. Protecting patients is an integral dimension of all healthcare, accompanied with honest discourse articulated through positive language at all times. How we speak matters just as much as speaking with honesty does. Understanding the patients’ views is paramount throughout the end-of-life journey.
- Open Access
- 1 January 2026
- Published by MedCrave Group Kft. in Hospice & Palliative Medicine International Journal
- Vol. 9 (1) , 19-23
Overriding policy on intravenous opioids versus subcutaneous route on rare occasions; ‘Rules are made to be broken’
Aim: The worldwide opioid crisis in recent decades has appropriately brought about much stricter rules and regulations concerning opioid use. Oral opioids remain first line unless other routes, subcutaneous or intravenous opioid are required in certain circumstances. Methods: Hospitals now have strict guidelines for how, where and by whom intravenous opioids are administered. In Palliative Care these opioid policies do not impact on our routine work but on rare occasions the intravenous route may become priority. Service providers need to know when mandatory intravenous opioid policy may require to be overridden. Results: Rare cases do occur when a strict policy has to be bypassed; then the policy bypass is required to be implemented appropriately; rapidly if at end-of-life to ensure patient's comfort and continuity of relief; ensure it does not put other staff in danger of breaching their scope of practice. Conclusions: Once all agree patient’s comfort requires a once off break in policy, collaboration to achieve best outcome for the patient is pivotal. New developments in opioid drug delivery systems deserve a mention to insure awareness of novel appropriate options for our patients. The technological evolution of orally disintegrating opioid tablets, ‘orodispersible’ that; rapidly dissolve once placed on the tongue; do not require swallowing is invigorating as routes of opioid drugs delivery is a daily issue in our prescribing decisions. Policies on opioids are imperative and strict, but if a rare scenario occurs, we are required to explore, educate and override the policy if it empowers the best comfort in dying patients. Up-to-date knowledge of new developments in opioid routes of delivery and old knowledge combined with new of the pharmacology of opioids is also essential as with any debate. “Problems are not stop signs, they are guidelines” Robert Schuller.
- 1 January 2026
- Published by MedCrave Group Kft. in Hospice & Palliative Medicine International Journal
- Vol. 9 (1) , 19-23
Open AccessOverriding policy on intravenous opioids versus subcutaneous route on rare occasions; ‘Rules are made to be broken’
Aim: The worldwide opioid crisis in recent decades has appropriately brought about much stricter rules and regulations concerning opioid use. Oral opioids remain first line unless other routes, subcutaneous or intravenous opioid are required in certain circumstances. Methods: Hospitals now have strict guidelines for how, where and by whom intravenous opioids are administered. In Palliative Care these opioid policies do not impact on our routine work but on rare occasions the intravenous route may become priority. Service providers need to know when mandatory intravenous opioid policy may require to be overridden. Results: Rare cases do occur when a strict policy has to be bypassed; then the policy bypass is required to be implemented appropriately; rapidly if at end-of-life to ensure patient's comfort and continuity of relief; ensure it does not put other staff in danger of breaching their scope of practice. Conclusions: Once all agree patient’s comfort requires a once off break in policy, collaboration to achieve best outcome for the patient is pivotal. New developments in opioid drug delivery systems deserve a mention to insure awareness of novel appropriate options for our patients. The technological evolution of orally disintegrating opioid tablets, ‘orodispersible’ that; rapidly dissolve once placed on the tongue; do not require swallowing is invigorating as routes of opioid drugs delivery is a daily issue in our prescribing decisions. Policies on opioids are imperative and strict, but if a rare scenario occurs, we are required to explore, educate and override the policy if it empowers the best comfort in dying patients. Up-to-date knowledge of new developments in opioid routes of delivery and old knowledge combined with new of the pharmacology of opioids is also essential as with any debate. “Problems are not stop signs, they are guidelines” Robert Schuller.
- Open Access
- 3 April 2025
- Published by Springer Nature in Current Oncology Reports
- Vol. 27 (5) , 584-600
Reflecting on Cancer Pain as Constant Acute Pain, not Chronic Pain. ‘Known Knowns, Known Unknowns, Unknown Unknowns’
Purpose of Review: to explore a paradigm shift in the definition of opioid-responsive cancer pain in this hypothesis-driven review. Opioid-responsive cancer pain may be misplaced within the definition of chronic pain, chronic pain takes three months to establish, early effective control is worthwhile to achieve. Recent: findings, from a bench-to-bed perspective, debates the interpretation of results supporting the hypothesis that opioid-responsive cancer pain could remain ‘constant acute pain’, with explanations, best solutions, for tolerance and/or addiction, in cancer patients compared to those with chronic pain from other conditions. Summary: Unraveling the unique apparent properties of opioid-responsive cancer pain empowers knowledge of the process by which acute pain may have the potential to remain acute in nature and not transition into chronic pain. Findings outlined defend the hypothesis of probable sustained acute nature of opioid-responsive cancer pain, importance of early, sustained pain control, opioid reduction and further exploration of this hypothesis in clinical practice.
- 3 April 2025
- Published by Springer Nature in Current Oncology Reports
- Vol. 27 (5) , 584-600
Open AccessReflecting on Cancer Pain as Constant Acute Pain, not Chronic Pain. ‘Known Knowns, Known Unknowns, Unknown Unknowns’
Purpose of Review: to explore a paradigm shift in the definition of opioid-responsive cancer pain in this hypothesis-driven review. Opioid-responsive cancer pain may be misplaced within the definition of chronic pain, chronic pain takes three months to establish, early effective control is worthwhile to achieve. Recent: findings, from a bench-to-bed perspective, debates the interpretation of results supporting the hypothesis that opioid-responsive cancer pain could remain ‘constant acute pain’, with explanations, best solutions, for tolerance and/or addiction, in cancer patients compared to those with chronic pain from other conditions. Summary: Unraveling the unique apparent properties of opioid-responsive cancer pain empowers knowledge of the process by which acute pain may have the potential to remain acute in nature and not transition into chronic pain. Findings outlined defend the hypothesis of probable sustained acute nature of opioid-responsive cancer pain, importance of early, sustained pain control, opioid reduction and further exploration of this hypothesis in clinical practice.
- Open Access
- 1 October 2024
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 42 (10) , 1073-1082
Case Series of Akathisia in Palliative Medicine: Patient Perspective and Efficacy of Procyclidine in Diagnosis and Management
Aims: Akathisia is a disturbing, reversible but under-diagnosed extrapyramidal side effect of medications used in palliative medicine. We assessed patients’ subjective experience of akathisia and response to procyclidine, an anticholinergic used to treat extrapyramidal effects. We also aimed to discuss future areas of research and alternatives to akathisia-causing medications. Methods: Suitable patients were retrospectively identified by palliative medicine physicians in a tertiary hospital and a chart review was undertaken. Information gathered included the account of their experience of akathisia, use of inciting medications, treatment, and outcome. Results: 20 patients were identified, 12 females, 8 males. Mean number of days on the inciting drug(s) to onset of akathisia symptoms was 18.1. Mean number of days from commencing inciting drug(s) to diagnosis was 20.9. Patients’ descriptions revealed similarities including feeling “locked in” and a need to constantly move. One patient described a “glass coffin” enclosing her. 16 patients had full response to treatment with procyclidine, 3 had partial response requiring up-titration of dosing, response was not documented in 1. Conclusions: Akathisia is an elusive symptom that can have dramatic reversibility when treated. Lack of recognition causes unnecessary patient suffering. Procyclidine appears to aid diagnosis and be an effective treatment. Protocols to reduce incidence and guide diagnosis and management are proposed. Further studies are required, in which subjective outcome measures are used and medications to treat akathisia are studied. Recognition remains challenging, causing significant distress for palliative patients, for whom quality of life is paramount.
- 1 October 2024
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 42 (10) , 1073-1082
Open AccessCase Series of Akathisia in Palliative Medicine: Patient Perspective and Efficacy of Procyclidine in Diagnosis and Management
Aims: Akathisia is a disturbing, reversible but under-diagnosed extrapyramidal side effect of medications used in palliative medicine. We assessed patients’ subjective experience of akathisia and response to procyclidine, an anticholinergic used to treat extrapyramidal effects. We also aimed to discuss future areas of research and alternatives to akathisia-causing medications. Methods: Suitable patients were retrospectively identified by palliative medicine physicians in a tertiary hospital and a chart review was undertaken. Information gathered included the account of their experience of akathisia, use of inciting medications, treatment, and outcome. Results: 20 patients were identified, 12 females, 8 males. Mean number of days on the inciting drug(s) to onset of akathisia symptoms was 18.1. Mean number of days from commencing inciting drug(s) to diagnosis was 20.9. Patients’ descriptions revealed similarities including feeling “locked in” and a need to constantly move. One patient described a “glass coffin” enclosing her. 16 patients had full response to treatment with procyclidine, 3 had partial response requiring up-titration of dosing, response was not documented in 1. Conclusions: Akathisia is an elusive symptom that can have dramatic reversibility when treated. Lack of recognition causes unnecessary patient suffering. Procyclidine appears to aid diagnosis and be an effective treatment. Protocols to reduce incidence and guide diagnosis and management are proposed. Further studies are required, in which subjective outcome measures are used and medications to treat akathisia are studied. Recognition remains challenging, causing significant distress for palliative patients, for whom quality of life is paramount.
- Open Access
- 13 March 2023
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 41 (1) , 113-118
Extreme Symptom Burden for Patients With COVID-19 at the End of Life; Extrapolation of Knowledge Gained to Achieve Sustained Comfort and Dignity for all Patients in Their Last Days of Life 1
Background: We describe two complex cases in the setting of COVID-19 at the End of Life, to enhance learning for all patients. Case Presentation: Maintenance of sustained comfort in two cases required multiple drugs, specifically selected for symptoms that necessitated three separate pumps delivering continuous 24-hour subcutaneous infusion. Case Management: Management of sustained comfort included opioid, midazolam, anti-secretory, diclofenac for intractable temperature, phenobarbital for extreme agitation, in one, where seizure activity was present, while insomnia, was a prominent feature of another. Management of Akatasia was also required. Case Outcome: Attention to each individual patient’s rapidly evolving symptoms, during the dying phase, with a thorough differential diagnosis, wa s vitally important in the context of a ‘Good Death’. This was achieved in both cases, reflected by evidence at the bedside of comfort and a minimum need for ‘as required’ drugs in the last days of life. Conclusions: COVID-19 being a new illness, we need to prospectively study the symptom burden/clustering at End of Life and learn from management of this new disease for other illnesses also. Further research is required to develop protocols on; when does Midazolam dose reach tolerance and when should an alternative drug such as phenobarbital for sustained Gamma-Aminobutyric Acid effects be initiated; examine the optimal approach to sustained temperature control; be cognisant of extrapyramidal side effects of drugs used at End of Life and consider looking at a lack of need for ‘as required’ drugs in the last days of life as an outcome measure of sustained comfort.
- 13 March 2023
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 41 (1) , 113-118
Open AccessExtreme Symptom Burden for Patients With COVID-19 at the End of Life; Extrapolation of Knowledge Gained to Achieve Sustained Comfort and Dignity for all Patients in Their Last Days of Life 1
Background: We describe two complex cases in the setting of COVID-19 at the End of Life, to enhance learning for all patients. Case Presentation: Maintenance of sustained comfort in two cases required multiple drugs, specifically selected for symptoms that necessitated three separate pumps delivering continuous 24-hour subcutaneous infusion. Case Management: Management of sustained comfort included opioid, midazolam, anti-secretory, diclofenac for intractable temperature, phenobarbital for extreme agitation, in one, where seizure activity was present, while insomnia, was a prominent feature of another. Management of Akatasia was also required. Case Outcome: Attention to each individual patient’s rapidly evolving symptoms, during the dying phase, with a thorough differential diagnosis, wa s vitally important in the context of a ‘Good Death’. This was achieved in both cases, reflected by evidence at the bedside of comfort and a minimum need for ‘as required’ drugs in the last days of life. Conclusions: COVID-19 being a new illness, we need to prospectively study the symptom burden/clustering at End of Life and learn from management of this new disease for other illnesses also. Further research is required to develop protocols on; when does Midazolam dose reach tolerance and when should an alternative drug such as phenobarbital for sustained Gamma-Aminobutyric Acid effects be initiated; examine the optimal approach to sustained temperature control; be cognisant of extrapyramidal side effects of drugs used at End of Life and consider looking at a lack of need for ‘as required’ drugs in the last days of life as an outcome measure of sustained comfort.
- 15 November 2022
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 13 (e3) , e953-e956
Central anticholinergic syndrome from hyoscine hydrobromide in an unresponsive patient
Terminal agitation is common and causes severe distress for patients and loved ones. Careful assessment is of paramount importance in identifying a cause. PA patient with gastric adenocarcinoma who was admitted with adverse effects post-chemotherapy deteriorated acutely with a presumed intracerebral event. Secretions were an issue and hyoscine hydrobromide was commenced. Within twenty-four hours, the patient became acutely agitated and did not respond to standard treatment.After careful clinical examination out-ruling other causes, toxic psychosis secondary to hyoscine hydrobromide was felt to be most likely. Rotating anti-secretories and commencing a phenobarbitone infusion to treat severe agitation resulted in prolonged comfort before death.Inhibiting cholinergic transmission at central muscarinic receptors can cause psychosis, delirium, etc. Hyoscine hydrobromide crosses the blood brain barrier. This case demonstrates that even in unresponsive patients, it may cause agitation. If standard therapies are failing to control agitation, all possibilities must be considered. Central side effects of hyoscine hydrobromide may be a rare but under-recognised cause of agitation. This case demonstrates how through careful clinical assessment of possible differentials, and prompt and effective management of the most likely causes of distress, lasting comfort can be achieved. Patient with gastric adenocarcinoma who was admitted with adverse effects post-chemotherapy deteriorated acutely with a presumed intracerebral event. Secretions were an issue and hyoscine hydrobromide was commenced. Within twenty-four hours, the patient became acutely agitated and did not respond to standard treatment.
- 15 November 2022
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 13 (e3) , e953-e956
Central anticholinergic syndrome from hyoscine hydrobromide in an unresponsive patient
Terminal agitation is common and causes severe distress for patients and loved ones. Careful assessment is of paramount importance in identifying a cause. PA patient with gastric adenocarcinoma who was admitted with adverse effects post-chemotherapy deteriorated acutely with a presumed intracerebral event. Secretions were an issue and hyoscine hydrobromide was commenced. Within twenty-four hours, the patient became acutely agitated and did not respond to standard treatment.After careful clinical examination out-ruling other causes, toxic psychosis secondary to hyoscine hydrobromide was felt to be most likely. Rotating anti-secretories and commencing a phenobarbitone infusion to treat severe agitation resulted in prolonged comfort before death.Inhibiting cholinergic transmission at central muscarinic receptors can cause psychosis, delirium, etc. Hyoscine hydrobromide crosses the blood brain barrier. This case demonstrates that even in unresponsive patients, it may cause agitation. If standard therapies are failing to control agitation, all possibilities must be considered. Central side effects of hyoscine hydrobromide may be a rare but under-recognised cause of agitation. This case demonstrates how through careful clinical assessment of possible differentials, and prompt and effective management of the most likely causes of distress, lasting comfort can be achieved. Patient with gastric adenocarcinoma who was admitted with adverse effects post-chemotherapy deteriorated acutely with a presumed intracerebral event. Secretions were an issue and hyoscine hydrobromide was commenced. Within twenty-four hours, the patient became acutely agitated and did not respond to standard treatment.
- 14 September 2022
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 13 (e3) , e839-e842
Methadone prescribed as an analgesic by a specialist palliative medicine team in an acute hospital inpatient setting: retrospective study
Emerging evidence suggests that methadone has a specific role in the management of treatment resistant cancer-related pain. Objectives To investigate the utilisation pattern, safety and efficacy of methadone prescribed as an analgesic for the management of complex cancer-related pain in an acute hospital inpatient setting. Methods A retrospective longitudinal observational study of patients prescribed methadone as an analgesic between April 2020 and July 2021 was performed. Changes in coprescribed baseline opioid, use of breakthrough opioid analgesic, patient rated pain scores and adverse side effects were analysed. Results 16 patients with complex cancer-related treatment resistant pain who were prescribed methadone were included in the study. Of the 16 patients, 14 patients had metastatic disease. Pain was classified in 14 patients as mixed nociceptive-neuropathic and in 2 patients as neuropathic. 13 patients were coprescribed methadone with a pre-established opioid. Methadone was associated with a statistically significant decrease in both opioid breakthrough analgesic by 61%±28% (pConclusion Methadone appears to have a specific role in the management of complex cancer pain, neuropathic pain, opioid-tolerance and opioid-induced hyperalgesia, which may be attributable to N-methyl-D-aspartate receptor antagonism.
- 14 September 2022
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 13 (e3) , e839-e842
Methadone prescribed as an analgesic by a specialist palliative medicine team in an acute hospital inpatient setting: retrospective study
Emerging evidence suggests that methadone has a specific role in the management of treatment resistant cancer-related pain. Objectives To investigate the utilisation pattern, safety and efficacy of methadone prescribed as an analgesic for the management of complex cancer-related pain in an acute hospital inpatient setting. Methods A retrospective longitudinal observational study of patients prescribed methadone as an analgesic between April 2020 and July 2021 was performed. Changes in coprescribed baseline opioid, use of breakthrough opioid analgesic, patient rated pain scores and adverse side effects were analysed. Results 16 patients with complex cancer-related treatment resistant pain who were prescribed methadone were included in the study. Of the 16 patients, 14 patients had metastatic disease. Pain was classified in 14 patients as mixed nociceptive-neuropathic and in 2 patients as neuropathic. 13 patients were coprescribed methadone with a pre-established opioid. Methadone was associated with a statistically significant decrease in both opioid breakthrough analgesic by 61%±28% (pConclusion Methadone appears to have a specific role in the management of complex cancer pain, neuropathic pain, opioid-tolerance and opioid-induced hyperalgesia, which may be attributable to N-methyl-D-aspartate receptor antagonism.
- Open Access
- 1 January 2019
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 26, 307-309
Mycobacterium goodii pneumonia: An unusual presentation of nontuberculous mycobacterial infection requiring a novel multidisciplinary approach to management
- 1 January 2019
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 26, 307-309
Open AccessMycobacterium goodii pneumonia: An unusual presentation of nontuberculous mycobacterial infection requiring a novel multidisciplinary approach to management
- Open Access
- 1 November 2005
- Published by BMJ in Archives of Disease in Childhood
- Vol. 90 (11) , 1206-1207
Melatonin: prescribing practices and adverse events
- 1 November 2005
- Published by BMJ in Archives of Disease in Childhood
- Vol. 90 (11) , 1206-1207
Open AccessMelatonin: prescribing practices and adverse events